Sitagliptin Enamine Impurity
| Product Name | Sitagliptin Enamine Impurity |
|---|---|
| Alternate Names | Sitagliptin Impurities, Impurities of Sitagliptin |
| CAT No. | CS-EO-01488 |
| CAS No. | 767340-03-4 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 405.30 g/mol |
| Mol. For. | C₁₆H₁₃F₆N₅O |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Sitagliptin |
| Canonical Smiles | C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C=C(CC3=CC(=C(C=C3F)F)F)N |
| InchIKey | RLSFDUAUKXKPCZ-UITAMQMPSA-N |
| Inchl | InChI=1S/C16H13F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4-6H,1-3,7,23H2/b9-5- |
| IUPAC | (Z)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)but-2-en-1-one |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Sitagliptin Enamine Impurity is an impurity that can be formed during the manufacturing process of Sitagliptin, a medication used to treat type 2 diabetes. This impurity is a chemical compound that is structurally similar to Sitagliptin, and is formed when the Sitagliptin molecule undergoes a chemical reaction in the presence of certain reactants.
The usage of Sitagliptin Enamine Impurity is strictly limited to research purposes, as it is not approved for use in humans. The impurity is typically used by pharmaceutical companies and research institutions to study the pharmacological properties of Sitagliptin and its potential side effects.
From a chemical perspective, Sitagliptin Enamine Impurity is a complex organic molecule that contains multiple functional groups, including an amine group, an imine group, and a pyrrolidine ring. The impurity is known to have a high affinity for the DPP-4 enzyme, which is the target of Sitagliptin and other similar medications.
Overall, the usage and chemical information of Sitagliptin Enamine Impurity is important for researchers and pharmaceutical companies to better understand the pharmacology of Sitagliptin and its potential side effects, and to develop more effective treatments for type 2 diabetes.
Get an Instant Quote
Related Compounds
Sitagliptin Amide impurity | Sitagliptin nitroso impurity | Sitagliptin impurity F | Sitagliptin Impurity 40 | Sitagliptin EP Impurity C | Sitagliptin Impurity 93 | Sitagliptin EP Impurity C Phosphate | Sitagliptin Impurity H | Sitagliptin FP Impurity D | Sitagliptin impurity J | Sitagliptin impurity H Hydrochloride | Sitagliptin Acid Pivaloyl impurity | Oxo Sitagliptin | Sitagliptin EP Impurity C | Sitagliptin tartrate hemihydrate | Sitagliptin Fumarate Adduct | Sitagliptin Triazecine Analog | Sitagliptin FP Impurity D (Z)-Isomer | Sitagliptin Impurity 84 | Sitagliptin impurity K | Sitagliptin impurity-4 | Sitagliptin Impurity 39 | N-Nitroso Sitagliptin Fumarate Adduct | Sitagliptin Impurity 62 | Sitagliptin impurity N | Sitagliptin impurity R | Sitagliptin EP Impurity A | Sitagliptin Impurity 61 | Rac-Sitagliptin Triazecine Analog | Sitagliptin Dioxo SODIUM Impurity | Sitagliptin hydroxylimine impurity | Sitagliptin isopropyl ester impurity | Sitagliptin Impurity 28 | Sitagliptin Triazecine Analog-D4 | Sitagliptin impurity G | Sitagliptin Amino Acid Impurity | Sitagliptin phosphate (Monohydrate) | Sitagliptin Phosphate Hydrate | SITAGLIPTIN FORMIC ACID ADDUCT | Sitagliptin impurity D | Sitagliptin EP Impurity E | Sitagliptin dioxo impurity | Sitagliptin N-formyl impurity | Sitagliptin impurity T | Sitagliptin Styrylacetyl Analogue | Sitagliptin impurity I | Sitagliptin N-Acetyl Impurity | Sitagliptin Pyrazine Impurity | Sitagliptin impurity L | Nitroso Sitagliptin |